18[F]F AraG

Drug Profile

18[F]F AraG

Alternative Names: 18[F]F-AraG; 18F-AraG; AraG-18[F]F; F18F-AraG; VisAcT

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer CellSight Technologies
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Bladder cancer; Cancer; Head and neck cancer

Most Recent Events

  • 08 May 2017 CellSight Technologies initiates a phase I trial in Cancer (Diagnosis) in USA (NCT03142204)
  • 01 May 2017 Phase-I clinical trials in Head and neck cancer (Diagnosis, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT03129061)
  • 01 May 2017 CellSight Technologies plans a phase I trial for Cancer (Diagnosis) in USA (NCT03142204)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top